Novo Nordisk · 13 hours ago
Internship - Security Strategy and Program Management
Plainsboro, NJ
Internship
Onsite
Intern
$52K/yr - $89K/yrNovo Nordisk is a global pharmaceutical company focused on creating lasting change for long-term health. The Security Strategy and Program Management intern will assist with the development, management, and execution of various security programs while monitoring worldwide events to evaluate threats to employees and locations.
BiotechnologyHealth CareMedicalPharmaceutical
No H1B
Responsibilities
Analyze daily developments to identify trends and patterns, provide forecasts, and make recommendations
Directly support travel security initiatives through preparation of location threat briefs
Provide research and analysis of personal protection situations for designated personnel
Conduct due diligence investigations on entities and persons as directed
Document workflows and processes using flowcharts to support risk analysis, mitigation planning, and policy development
Qualification
Required
Must be a current student enrolled or recently graduated (graduation date no earlier than May 2026) at/from an accredited college or university pursuing at least a bachelor's degree
Strong academic record with a preferred cumulative GPA of 3.0 or higher
Conscientious self-starter with good organizational skills, project management skills and attention to detail
Ability to balance multiple projects and priorities, must be able to multi-task
Strong interpersonal communication and ability to collaborate with teams; must effectively operate independently, across functional lines, and with internal customers
Demonstrated personal initiative, self-motivation, flexibility, adaptability and willingness to learn
Proficient in Microsoft Office Tools including Word, Excel, PowerPoint, etc
Preferred
A completed or in progress undergraduate or graduate degree in Criminal Justice, Security, Intelligence, Geopolitics or a related discipline preferred
Company
Novo Nordisk
Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases.
Founded in 1923
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$22M2018-12-05Post Ipo Equity· $22M
1981-07-09IPO
Leadership Team
Lars Fruergaard Jørgensen
President and CEO
Lars Sorensen
President & CEO
Recent News
Labiotech UG
2026-01-24
bloomberglaw.com
2026-01-24
Company data provided by crunchbase